ALLO
NASDAQ · Biotechnology
Allogene Therapeutics Inc
$2.01
+0.04 (+2.03%)
Analyst Consensus
Strong Buy
18
Analysts
High
Coverage
Price Target
Analyst Price Target
+995.0% upside
Low Target
$17.29
Average Target
$22.01
High Target
$30.07
Current Price
$2.01
Current
$2.01
$2.01
Target
$22.01
$22.01
$17.29
$22.01 avg
$30.07
Scenario Analysis
Bear Case
$17.29
760.2%
Low target
Base Case
$22.01
+995.0%
Avg target
Bull Case
$30.07
+1,396.0%
High target
Risk/Reward
1.8x
Balanced
Price in Context
52-Week High
$4.46
-54.9% from high
52-Week Low
$0.98
+105.1% from low
Target vs 52W High
$22.01
+393.5% vs high
Next Earnings Report
Aug 12, 2026 · After Market Close
2d
until earnings
EPS Est: $-0.17
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 38 | 82% | $257.58 | +4.7% |
| AMGN | Hold | 43 | 49% | $190.87 | -53.6% |
| GILD | Strong Buy | 37 | 81% | $362.68 | +172.3% |
| VRTX | Strong Buy | 37 | 81% | $438.34 | -11.6% |
| REGN | Buy | 37 | 70% | $76.80 | -90.2% |
| NTRA | Strong Buy | 30 | 87% | $142.91 | -55.6% |
| RVMD | Strong Buy | 28 | 93% | $114.11 | -44.4% |
| BIIB | Buy | 43 | 67% | $91.45 | -56.0% |